Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1

Abstract Background Docosahexaenoic acid (DHA) is a long chain n-3 polyunsaturated fatty acid that has anticancer activity. Heme oxygenase 1 (HO-1) is a potential therapeutic target due to its cytoprotective activity in cancer cells. We recently reported that DHA induces HO-1 gene transcription in h...

Full description

Bibliographic Details
Main Authors: Yang Jiao, Tanya Watts, Jing Xue, Bethany Hannafon, Wei-Qun Ding
Format: Article
Language:English
Published: BMC 2018-10-01
Series:BMC Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12885-018-4946-9
_version_ 1819151900526772224
author Yang Jiao
Tanya Watts
Jing Xue
Bethany Hannafon
Wei-Qun Ding
author_facet Yang Jiao
Tanya Watts
Jing Xue
Bethany Hannafon
Wei-Qun Ding
author_sort Yang Jiao
collection DOAJ
description Abstract Background Docosahexaenoic acid (DHA) is a long chain n-3 polyunsaturated fatty acid that has anticancer activity. Heme oxygenase 1 (HO-1) is a potential therapeutic target due to its cytoprotective activity in cancer cells. We recently reported that DHA induces HO-1 gene transcription in human cancer cells by augmenting the degradation of Bach1 protein, which functions as a negative regulator of HO-1. Since the degradation of Bach1 protein relies on protein phosphorylation, we hypothesized that DHA-induced HO-1 gene transcription could be attenuated by kinase inhibitors, resulting in an enhanced cytotoxicity. Sorafenib, a tyrosine kinase inhibitor, was first applied to test our hypothesis. Methods Human cancer cell lines and a xenograft nude mouse model were applied to test our hypothesis. Gene expression was analyzed by western blot analysis and reporter gene assay. Cell viability was analyzed using a colorimetric assay. Isobologram was applied to analyze drug action. Results Pretreatment of cancer cells with Sorafenib significantly attenuated DHA-induced degradation of Bach1 protein. Consequently, DHA-induced HO-1 gene transcription was reversed by Sorafenib as evidenced by western blot and reporter gene analysis. Sorafenib acted synergistically with DHA to suppress cancer cell viability in various human cancer cell lines and suppressed tumor xenograft growth in mice fed a fish oil enriched diet (high n-3/DHA), as compared to mice fed a corn oil (high n-6) diet. Screening of the NCI-Oncology Drug Set IV identified a group of anticancer compounds, including Sorafenib, which enhanced DHA’s cytotoxicity, as well as a set of compounds that attenuated DHA’s cytotoxicity. Conclusions We demonstrate that sorafenib attenuates DHA-induced HO-1 expression and acts in synergy with DHA to suppress cancer cell viability and tumor growth. Considering the known health benefits of DHA and the clinical effectiveness of Sorafenib, their combination is an attractive therapeutic strategy against cancer.
first_indexed 2024-12-22T14:40:45Z
format Article
id doaj.art-89e25490df4b4171a2e47e4bf162c513
institution Directory Open Access Journal
issn 1471-2407
language English
last_indexed 2024-12-22T14:40:45Z
publishDate 2018-10-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj.art-89e25490df4b4171a2e47e4bf162c5132022-12-21T18:22:33ZengBMCBMC Cancer1471-24072018-10-0118111010.1186/s12885-018-4946-9Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1Yang Jiao0Tanya Watts1Jing Xue2Bethany Hannafon3Wei-Qun Ding4Department of Pathology, University of Oklahoma Health Sciences CenterDepartment of Pathology, University of Oklahoma Health Sciences CenterDepartment of Pathology, University of Oklahoma Health Sciences CenterDepartment of Pathology, University of Oklahoma Health Sciences CenterDepartment of Pathology, University of Oklahoma Health Sciences CenterAbstract Background Docosahexaenoic acid (DHA) is a long chain n-3 polyunsaturated fatty acid that has anticancer activity. Heme oxygenase 1 (HO-1) is a potential therapeutic target due to its cytoprotective activity in cancer cells. We recently reported that DHA induces HO-1 gene transcription in human cancer cells by augmenting the degradation of Bach1 protein, which functions as a negative regulator of HO-1. Since the degradation of Bach1 protein relies on protein phosphorylation, we hypothesized that DHA-induced HO-1 gene transcription could be attenuated by kinase inhibitors, resulting in an enhanced cytotoxicity. Sorafenib, a tyrosine kinase inhibitor, was first applied to test our hypothesis. Methods Human cancer cell lines and a xenograft nude mouse model were applied to test our hypothesis. Gene expression was analyzed by western blot analysis and reporter gene assay. Cell viability was analyzed using a colorimetric assay. Isobologram was applied to analyze drug action. Results Pretreatment of cancer cells with Sorafenib significantly attenuated DHA-induced degradation of Bach1 protein. Consequently, DHA-induced HO-1 gene transcription was reversed by Sorafenib as evidenced by western blot and reporter gene analysis. Sorafenib acted synergistically with DHA to suppress cancer cell viability in various human cancer cell lines and suppressed tumor xenograft growth in mice fed a fish oil enriched diet (high n-3/DHA), as compared to mice fed a corn oil (high n-6) diet. Screening of the NCI-Oncology Drug Set IV identified a group of anticancer compounds, including Sorafenib, which enhanced DHA’s cytotoxicity, as well as a set of compounds that attenuated DHA’s cytotoxicity. Conclusions We demonstrate that sorafenib attenuates DHA-induced HO-1 expression and acts in synergy with DHA to suppress cancer cell viability and tumor growth. Considering the known health benefits of DHA and the clinical effectiveness of Sorafenib, their combination is an attractive therapeutic strategy against cancer.http://link.springer.com/article/10.1186/s12885-018-4946-9SorafenibDocosahexaenoic acidCancerHeme oxygenase 1Synergy
spellingShingle Yang Jiao
Tanya Watts
Jing Xue
Bethany Hannafon
Wei-Qun Ding
Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1
BMC Cancer
Sorafenib
Docosahexaenoic acid
Cancer
Heme oxygenase 1
Synergy
title Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1
title_full Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1
title_fullStr Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1
title_full_unstemmed Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1
title_short Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1
title_sort sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability a role of heme oxygenase 1
topic Sorafenib
Docosahexaenoic acid
Cancer
Heme oxygenase 1
Synergy
url http://link.springer.com/article/10.1186/s12885-018-4946-9
work_keys_str_mv AT yangjiao sorafenibanddocosahexaenoicacidactinsynergytosuppresscancercellviabilityaroleofhemeoxygenase1
AT tanyawatts sorafenibanddocosahexaenoicacidactinsynergytosuppresscancercellviabilityaroleofhemeoxygenase1
AT jingxue sorafenibanddocosahexaenoicacidactinsynergytosuppresscancercellviabilityaroleofhemeoxygenase1
AT bethanyhannafon sorafenibanddocosahexaenoicacidactinsynergytosuppresscancercellviabilityaroleofhemeoxygenase1
AT weiqunding sorafenibanddocosahexaenoicacidactinsynergytosuppresscancercellviabilityaroleofhemeoxygenase1